Background: Effective treatment and early diagnosis is essential for patients with hepatocellular carcinoma. Nowadays, there is an increasing interest in the utilization of AFP/Fth as an endogenous contrast agent for the early diagnosis of liver cancers. The transfection of AFP/Fth also leads to a considerable upregulation of transferrin receptors (TfR), which might be a potential target for an enhanced delivery of nanomedicines. However, there is no information regarding the utilization of overexpressed TfR for the treatment of liver cancers. Thus, the objective of our study was to investigate whether the transfection of AFP/Fth could be used for the early diagnosis, but also for an enhanced treatment of live cancers. Results: It was found that both of ferritin and TfR were upregulated after the transfection of AFP/Fth plasmid. The transfected cells showed a higher uptake of ferric ion than the un-transfected ones, resulting in a lower T2WI intensity. This result was due to the upregulation of ferritin in transfected cells, suggesting that transfection of AFP/Fth plasmid could be a potential strategy for early diagnosis of liver cancer. As compared with the un-transfected cells, the transfected cells showed a higher uptake of transferrin-modified liposomes, which was due to the specific interaction between transferrin with TfR overexpressed on the transfected cells. This is also the reason why the transferrin modified doxorubicin loaded liposomes (Tf-LP/DOX) showed better in vitro and in vivo anticancer ability than the LP/DOX. This results also suggested that transfection of AFP/Fth could result in an enhanced therapy of liver cancer. Conclusions: Transfection of AFP/Fth could be used for the early diagnosis, but also for an enhanced treatment of live cancers.